{"Title": "Developments over the last 60 years in diffuse large B-cell lymphomas", "Year": 2020, "Source": "Br. J. Haematol.", "Volume": "191", "Issue": 4, "Art.No": null, "PageStart": 552, "PageEnd": 557, "CitedBy": 0, "DOI": "10.1111/bjh.17154", "Link": "https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85095933540&origin=inward", "Abstract": "\u00a9 2020 British Society for Haematology and John Wiley & Sons LtdAt the time of the formation of the British Society of Haematology diffuse large B-cell lymphoma was not recognised as a specific entity and was included in the category of \u2018large cell\u2019 or \u2018aggressive\u2019 lymphomas. These were fatal in 95% of cases. Today the cure rate in adults entered into clinical trials is ~70% and a large number of British physicians have contributed to this progress.", "AuthorKeywords": ["biology", "classification", "diffuse large B-cell lymphoma", "treatment"], "IndexKeywords": null, "DocumentType": "Journal", "PublicationStage": null, "OpenAccess": null, "EID": "2-s2.0-85095933540", "SubjectAreas": [["Hematology", "MEDI", "2720"]], "AuthorData": {"14634099500": {"Name": "Linch D.", "AuthorID": "14634099500", "AffiliationID": "60022148", "AffiliationName": "Department of Haematology, University College London (UCL) Cancer Institute"}}}